Cytovene-IV Labeling Updated to Include Additional Fertility Impairment Data

By August 10, 2018

Cytovene-IV is a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor.

Prophylactic letermovir significantly reduces cytomegalovirus infection after transplantation

January 01, 2018

Compared to placebo, letermovir prophylaxis significantly decreased the incidence of cytomegalovirus (CMV) infection through 24 weeks following hematopoietic stem cell transplantation (HSCT).